Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Strategies

Set Alert for Pricing Strategies

Medicines For Ireland Appoints New Chairs Following Framework Agreement

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Executive Changes Ireland

Multiple Molecules See UK Prices More Than Double In December

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Market Intelligence Pricing Strategies

AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near

AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.

Biosimilars Biologics

Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars

Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.

Biosimilars Pricing Strategies

Manchin Pushback Bad News For Biden But Good News For Biosimilars

Joe Manchin’s refusal to vote in favor of the Biden administration’s Build Back Better legislation could prove to be a boon for the US biosimilars industry, following weeks of condemnation from the Association for Accessible Medicines.

Biosimilars Legislation

Irish Industry Pact Offers Stability And Visibility

A four-year agreement reached between Medicines for Ireland and the Irish government offers suppliers visibility and stability thanks to a combination of clear pricing mechanisms as well as the promise of uptake drivers, the off-patent industry association says.

Ireland Policy

Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval

As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.

Biosimilars Approvals

Topiramate Tablets Dominate November Rises In UK

Topiramate tablets took four places in our table of average UK generic price rises for November 2021, as prices as much as trebled for the epilepsy treatment. However, one product ranked even higher with a 231% average price rise.

Market Intelligence Pricing Strategies

MPP Strikes Deal For Long-Acting Injectable HIV Candidate

The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.

Generic Drugs Pricing Strategies
See All
UsernamePublicRestriction

Register